Aplidin as a potential adjunct to radiation therapy: In vitro studies

References

• Arbeit JM, Brown JM, Chao KSC, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D. 2006. International Journal of Radiation Biology 82:699–757.
   PubMedGoogle Scholar
• Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. 2005. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Annals of Oncology 16:1667–1674.
   PubMed Web of Science ®Google Scholar
• Chu K, Teele N, Dewey MW, Albright N, Dewey WC. 2004. Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3σ and CDKN1A (p21) knockout cell lines. Radiation Research 162:270–286.
   PubMed Web of Science ®Google Scholar
• Donnelly ET, Kelley M, Rockwell S. 2004. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.Cancer Chemotherapy Pharmacology 53:43–50.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW. 2009. Relationships between cycling hypoxia, HIF-1, angiogenesis, and oxidative stress: The Fialla Lecture, Radiation Research 172:653–665.
   Google Scholar
• Elkind MM, Whitmore GF. 1967. The radiobiology of cultured mammalian cells. New York: Gordon and Breach.
   Google Scholar
• Gajate C, Mollinedo F. 2005. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. Journal of Biological Chemistry 280:11641–11647.
   PubMed Web of Science ®Google Scholar
• García-Fernández LF, Reyes F, Sánchez-Puelles JM. 2002. The marine pharmacy: New antitumoral compounds from the sea. 2002. Pharmaceutical News 9:495–501.
   Google Scholar
• González-Santiago L, Alfonso P, Suárez Y, Núñez A, García-Fernández LF, Alvarez E, Muñoz A, Casal JI. 2007. Proteomic analysis of the resistance to Aplidin in human cancer cells. Journal of Proteome Research 6:1286–1294.
   PubMedGoogle Scholar
• González-Santiago L, Suárez Y, Zarich N, Muñoz-Alonso MJ, Cuadrado A, Martínez T, Goya L, Iradi A, Sáez-Tormo G, Maier JV, Moorthy A, Cato AC, Rojas JM, Muñoz A. 2006. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differentiation 13:1968–1981.
   PubMed Web of Science ®Google Scholar
• Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GS, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D. 2007. Aplidin synergizes with cytosine arabinoside: Functional relevance of mitochondria in Aplidin-induced cytotoxicity. Leucemia 21:2399–2405.
   Google Scholar
• Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gasate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munsi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G. 2008. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.Cancer Research 68:5216–5225.
   PubMed Web of Science ®Google Scholar
• Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A. 2007. Levels of p27kip1 determine Aplidin sensitivity. Molecular Cancer Therapeutics 6:1310–1316.
   PubMedGoogle Scholar
• Muñoz-Alonso MJ, González-Santiago L, Zarich N, Martínez T, Alvarez E, Rojas JM, Muñoz A. 2008. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. Journal of Pharmacology Experimental Therapeutics 324:1093–1101.
   PubMed Web of Science ®Google Scholar
• Rinehart KI. 2000. Antitumor compounds from tunicates. Medical Research Reviews 20:1–27.
   PubMed Web of Science ®Google Scholar
• Rockwell S, Frindel E, Tubiana M. 1976. A technique for determining the proportion of the clonogenic cells in S phase in EMT6 cell cultures and tumors. Cell Tissue Kinetics 9:313–323.
   PubMedGoogle Scholar
• Rockwell S. 1977. In vivo-in vitro tumor systems: New models for studying the response of tumors to therapy. Laboratory Animal Science 27:831–851.
   PubMedGoogle Scholar
• Rockwell S, Schulz RJ. 1984. Failure of 5-thio-D-glucose to alter cell survival in irradiated or unirradiated EMT6 tumors. Radiation Research 100:527–535.
   PubMed Web of Science ®Google Scholar
• Rockwell S, Grindey GB. 1992. Effect of 2′, 2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncology Research 4:151–155.
   PubMedGoogle Scholar
• Rockwell S. 1992. Use of hypoxia-directed drugs in the therapy of solid tumors. Seminars in Oncology 19:29–40.
   PubMedGoogle Scholar
• Rockwell S. 1997. Oxygen delivery: Implications for the biology and therapy of solid tumors. Oncology Research 9:383–390.
   PubMedGoogle Scholar
• Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. 2009. Hypoxia and radiation therapy: Past history, ongoing research, and future promise, Current Molecular Medicine 9:442–458.
   PubMed Web of Science ®Google Scholar
• Rockwell S. 2009. Tumor cell survival. In: Teicher BA, editor. Tumor models in cancer research. 2nd ed. New York: Humana Press (in press).
   Google Scholar
• Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL. 2006. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemotherapy Pharmacology 57:7–14.
   PubMed Web of Science ®Google Scholar
• Suárez Y, González-Santiago L, Zarich N, Dávalos A, Aranda JF, Alonso MA, Lasunción MA, Rojas JM, Muñoz A. 2006. Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content. Molecular Pharmacology 70:1654–1663.
   PubMed Web of Science ®Google Scholar